Q1 2025 sales update
The Q1 2025 sales update have been published on April 16, 2025 at 7H00 and a conference call took place at 14H00 CET.
The latest highlights from Investor Relations
Find out what’s been happening at Ipsen Investor Relations lately – including financial results, announcements, IR events, and more.
– 28 May 2024
Annual General Meeting of Ipsen S.A. held on 28 May 2024
– 05 September 2022
First international Fibrodysplasia Ossificans Progressiva (FOP) Burden of Illness Survey reveals extent of social, economic,…
– 08 July 2024
Half-year statement of IPSEN liquidity agreement – 2024 06 30
– 15 January 2022
Health Canada approves Ipsen’s Sohonos (palovarotene capsules) as the first approved treatment for fibrodysplasia ossificans…
INVESTING FOR GROWTH
We see everyone within the Ipsen investor community as a valued stakeholder who helps drive our overall success. Dedicated to transparency and ethical decision-making, we aim to provide investors with the resources they need to understand our company and how we plan to reach our ambitious targets.
Underpinned by a robust balance sheet and strong cash generation, we have the ambition to replenish our pipeline. With a successful strategy, we’re proud to be backed by an investor community that recognizes our positive progress.
Ipsen in Brief
Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.
Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.
Strong results backed by innovation
Our vision is to be a leading global mid-size biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience. In 2023, we delivered solid results ahead of new launches in 2024. Our growth is balanced across geographies, and we continue to strengthen our pipeline across our therapy areas for long-term, sustainable growth.
Download Ipsen’s Annual ReportInvestor events
We are dedicated to providing investors with the tools they need to understand our company and goals. Our events offer investors the opportunity to meet our management and investor-relations team and learn more about our strategy.
Pipeline
Innovating for a healthy tomorrow. Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across Oncology, Rare Disease and Neuroscience.
Shareholder information
We aim to transparently communicate to our investor community our analyst coverage, ADR program and shareholding structure.
Learn more
Regulated information
Information on voting rights updates, combined shareholders’ meeting and our share buyback program. View the publications and press releases related to regulated information.
Learn moreFIVE-YEAR STOCK INFORMATION
Share price and stock information, benchmark, orders, transactions: discover the data related to Ipsen’s shares.
Your dedicated contacts
-
Untitled
-